Q-VD-OPh hydrate 

To Order Contact us: stephen@expresspharmapulse.com

Q-VD-OPh
1170-3 each
EUR 529.2

Q-VD-OPh
1170-5 each
EUR 874.8

Q-VD-OPh
1170-50 each Ask for price

Q-VD(OMe)-OPh
A8165-1 1 mg
EUR 212.4
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh
A8165-10 10 mg
EUR 756
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh
A8165-25 25 mg
EUR 1173.6
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh
A8165-5 5 mg
EUR 477.6
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh
A8165-5.1 10 mM (in 1mL DMSO)
EUR 853.2
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh
A8165-S Evaluation Sample
EUR 97.2
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

(R)-Q-VD-OPh
HY-12305A 10mg
EUR 308.4

EZSolution? Q-VD-OPh
1173-1 each
EUR 248.4

Q-VD(OMe)-OPh
27640-1 5 mg
EUR 380
Description: Q-VD-(OMe)-Ph is a second-generation capase inhibitor that is highly potent, brain and cell permeable, irreversible and nontoxic. Q-VD-(OMe)-Ph can inhibit caspase-3 ( IC50=25 nm), caspase-1 (IC50=50 nM), caspase-8 (IC50=100 nM) and caspase-9 (IC50=430 nM).

Q-VD(OMe)-OPh
27640-2 10 mg
EUR 565
Description: Q-VD-(OMe)-Ph is a second-generation capase inhibitor that is highly potent, brain and cell permeable, irreversible and nontoxic. Q-VD-(OMe)-Ph can inhibit caspase-3 ( IC50=25 nm), caspase-1 (IC50=50 nM), caspase-8 (IC50=100 nM) and caspase-9 (IC50=430 nM).

EZSolution? Q-VD-OPh, Negative Control
1174-1 each
EUR 248.4

Pan-caspase inhibitor, Q-VD(OMe)-OPh
2787-1 each
EUR 314.4

Pan-caspase inhibitor, Q-VD(OMe)-OPh
2787-5 each
EUR 966

Q-VE-Oph
GL5302-1MG 1 mg
EUR 302.4

EZSolution? Q-DEVD-OPh
1178-1 each
EUR 326.4

Caspase-3 Inhibitor Q-DEVD-OPh
1175-1 each
EUR 326.4

Caspase-3 Inhibitor Q-DEVD-OPh
1175-3 each
EUR 639.6

Caspase-3 Inhibitor Q-DEVD-OPh
1175-5 each
EUR 966

Caspase-8 Inhibitor, Q-IETD-OPh
1176-1 each
EUR 366

Caspase-8 Inhibitor, Q-IETD-OPh
1176-3 each
EUR 823.2

Caspase-8 Inhibitor, Q-IETD-OPh
1176-5 each
EUR 1188

Caspase-9 Inhibitor, Q-LEHD-OPh
1177-1 each
EUR 352.8

Caspase-9 Inhibitor, Q-LEHD-OPh
1177-3 each
EUR 810

Caspase-9 Inhibitor, Q-LEHD-OPh
1177-5 each
EUR 1161.6

VD/ Rat VD ELISA Kit
ELA-E0917r 96 Tests
EUR 1063.2

VD-PEG-NH2,2K
33-HE090005-2K
  • EUR 681.60
  • EUR 1909.20
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

QVD-OPh Negative Control
1171-1 each
EUR 248.4

QVD-OPh Negative Control
1171-3 each
EUR 483.6

QVD-OPh Negative Control
1171-5 each
EUR 705.6

Ivacaftor hydrate
A3511-10 10 mg
EUR 320.4
Description: Description:IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1]Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis.

Ivacaftor hydrate
A3511-100 100 mg
EUR 1470
Description: Description:IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1]Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis.

Ivacaftor hydrate
A3511-5 5 mg
EUR 211.2
Description: Description:IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1]Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis.

Ivacaftor hydrate
A3511-50 50 mg
EUR 1036.8
Description: Description:IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1]Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis.

CHAPS Hydrate
20-abx082319
  • EUR 226.80
  • EUR 8328.00
  • EUR 360.00
  • 1 g
  • 1 kg
  • 5 g

Entecavir Hydrate
A1767-25 25 mg
EUR 448.8
Description: Entecavir hydrate is a reverse transcriptase inhibitor.Reverse transcriptase (RT) is used to generate complementary DNA (cDNA) from an RNA template, which is mainly associated with retroviruses, such as HBV.

Entecavir Hydrate
A1767-5 5 mg
EUR 170.4
Description: Entecavir hydrate is a reverse transcriptase inhibitor.Reverse transcriptase (RT) is used to generate complementary DNA (cDNA) from an RNA template, which is mainly associated with retroviruses, such as HBV.

Entecavir Hydrate
A1767-5.1 10 mM (in 1mL DMSO)
EUR 135.6
Description: Entecavir hydrate is a reverse transcriptase inhibitor.Reverse transcriptase (RT) is used to generate complementary DNA (cDNA) from an RNA template, which is mainly associated with retroviruses, such as HBV.

Doripenem Hydrate
A2036-10 10 mg
EUR 122.4
Description: Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1].

Doripenem Hydrate
A2036-100 100 mg
EUR 393.6
Description: Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1].

Doripenem Hydrate
A2036-5.1 10 mM (in 1mL DMSO)
EUR 135.6
Description: Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1].

Doripenem Hydrate
A2036-50 50 mg
EUR 268.8
Description: Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1].

Calcipotriol hydrate
20-abx185970
  • EUR 1045.20
  • EUR 477.60
  • 25 mg
  • 5 mg

Felbamate hydrate
B1145-10 10 mg
EUR 166.8
Description: Felbamate hydrate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .

Felbamate hydrate
B1145-50 50 mg
EUR 428.4
Description: Felbamate hydrate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .

Posaconazole hydrate
B1225-10 10 mg
EUR 258
Description: Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme

Fluconazole hydrate
B1226-1000 1 g
EUR 129.6
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.

Fluconazole hydrate
B1226-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.

Fluconazole hydrate
B1226-5000 5 g
EUR 268.8
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.

Tenofovir hydrate
B1252-5 5 mg
EUR 150
Description: Tenofovir hydrate is an inhibitor of reverse transcriptase used for the treatment of the human immunodeficiency virus 1(HIV-1) and hepatitis B [1].Tenofovir hydrate is an antiviral pro-drug and the class of nucleoside reverse transcriptase inhibitor.

Tenofovir hydrate
B1252-5.1 10 mM (in 1mL DMSO)
EUR 158.4
Description: Tenofovir hydrate is an inhibitor of reverse transcriptase used for the treatment of the human immunodeficiency virus 1(HIV-1) and hepatitis B [1].Tenofovir hydrate is an antiviral pro-drug and the class of nucleoside reverse transcriptase inhibitor.

Bosentan Hydrate
B1521-100 100 mg
EUR 254.4
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Bosentan Hydrate
B1521-200 200 mg
EUR 366
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Bosentan Hydrate
B1521-5.1 10 mM (in 1mL DMSO)
EUR 150
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Bosentan Hydrate
B1521-50 50 mg
EUR 170.4
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Bosentan Hydrate
B1521-500 500 mg
EUR 686.4
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Cefprozil hydrate
B2142-10 10 mg
EUR 370.8
Description: Cefprozil hydrate

Cefprozil hydrate
B2142-50 50 mg
EUR 1004.4
Description: Cefprozil hydrate

Q-VD-OPh hydrate